Form 4: Cellectar Biosciences Director Asher Chanan-Khan Granted Stock Options Following Stockholder Approval

Director Asher Chanan-Khan received stock options for 60,000 shares of Cellectar Biosciences after stockholder approval of the amended 2021 Stock Incentive Plan.

Summary

• Asher Chanan-Khan, a director of Cellectar Biosciences, Inc., was granted stock options to purchase 60,000 shares of common stock.
• The options were granted on June 14, 2024, following stockholder approval of Cellectar's amended 2021 Stock Incentive Plan at the company's 2024 Annual Meeting of Stockholders.
• The exercise price of the stock options is $2.58 per share.
• The options vest in full on December 22, 2024, contingent upon the reporting person's continued service through that date.
• The options expire on December 22, 2033.

Sentiment

Score: 7

Explanation: The granting of stock options is a positive sign, indicating alignment between management and shareholders. The sentiment is moderately positive.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• Stockholder approval of the amended 2021 Stock Incentive Plan indicates support for the company's compensation strategy.

Future Outlook

The director's continued service is required for the options to vest, incentivizing their ongoing contribution to the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• Shareholders may view the granting of stock options positively, as it aligns the director's interests with increasing shareholder value.
• The director is incentivized to continue contributing to the company's success to ensure the options vest.

Key Dates

Keywords

stock options, Cellectar Biosciences, director, stockholder approval, Form 4, CLRB, incentive plan